Biofrontera Ag Company Profile (LON:B8F)

Analyst Ratings

Consensus Ratings for Biofrontera Ag (LON:B8F) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Biofrontera Ag (LON:B8F)
Show:
DateFirmActionRatingPrice TargetActions
2/17/2016Shore CapitalReiterated Ratinghouse stockView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/10/2015FinnCapReiterated RatingUnder ReviewView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Biofrontera Ag (LON:B8F)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Biofrontera Ag (LON:B8F)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Biofrontera Ag (LON:B8F)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Biofrontera Ag (LON:B8F)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Biofrontera Ag (LON:B8F)
DateHeadline
07/28/16 11:28 AMBiofrontera : Receives Favourable CHMP Assessment for Field-Directed Therapy and Files BCC Application
07/28/16 11:28 AMBiofrontera AG: Biofrontera Receives Favourable CHMP Assessment for Field-Directed Therapy and Files BCC Application
07/25/16 07:31 AMPTA-News: Biofrontera AG: Biofrontera to Present at the Canaccord Genuity Annual Growth Conference
07/25/16 07:31 AMBiofrontera AG: Biofrontera to Present at the Canaccord Genuity Annual Growth Conference
07/13/16 08:10 PMAd-hoc: Biofrontera AG and Maruho Initiate Joint Project to Explore Development Opportunities
06/30/16 08:08 PMBiofrontera : Initiates Phase III Trial of Ameluz® in Combination with Daylight-PDT
06/23/16 10:10 PMBiofrontera AG: Biofrontera Progresses with Expansion of U.S. Subsidiary with Key Personnel Hires
06/23/16 10:10 PMBiofrontera : Progresses with Expansion of U.S. Subsidiary with Key Personnel Hires
05/26/16 04:06 PMBiofrontera AG: Biofrontera Reports First Quarter 2016 Financial Results and Business Update - Leverkusen (pta008/25.05.2016/09:15) - Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today reported its financial results for the first quarter for the three month period ending March 31, 2016 and provided an ...
05/23/16 01:36 AMNotice of quarterly report of 2016 - [at noodls] - Press Release News Release Biofrontera AG Leverkusen, Germany, 23 May 2016 - Biofrontera AG (AIM: B8F), the specialist for the treatment of sun-induced skin cancer, will be announcing its financial results ...
04/07/16 07:02 AMBiofrontera AG: Notice of Annual Results 2016 -
03/05/16 01:52 PMPTA-News: Biofrontera AG: Results of Phase III clinical trial evaluating BF-200 ALAfor treatment of basal cell carcinoma (BCC) - Enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer ... Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics ...
02/16/16 01:55 PMPTA-PVR : Nexus AG: Release according to Article 26, Section 1 of the WpHG - Biofrontera AG (FSE: B8F), der Spezialist für sonneninduzierten Hautkrebs, präsentiert Ergebnisse von drei pivotalen Phase III-Studien für das Medikament BF-200 AL... DOW-FLASH: Dow dämmt Verlust ein - Händler: Hoffnung auf Opec-Fördersenkung 11.02 ...
02/16/16 01:55 PMBiofrontera : AG: AG resolves on capital increase - The issuer is solely responsible for the content of this announcement. Leverkusen, Germany, February 16, 2016 - The Management Board of Biofrontera AG (FSE: B8F) has resolved on 12 February 2016, with the approval of the Supervisory Board, to increase the ...
02/16/16 01:55 PMBiofrontera AG: Biofrontera AG Resolves On Capital Increase - Leverkusen, Germany, Feb. 16, 2016 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG (FSE: B8F) has resolved on 12 February 2016, with the approval of the Supervisory Board, to increase the registered share capital of the Company by up to EUR ...
02/11/16 01:45 PMBiofrontera AG: Data from pivotal Phase III studies with BF-200 ALA introduced to US dermtologists - Poster and oral presentations on phase III data with BF-200 ALA at the 14th South Beach Symposium Leverkusen, Germany (pta026/11.02.2016/16:30) - Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, presents data from three pivotal Phase ...
02/11/16 01:45 PMBiofrontera AG: Pivotal Phase III Data Demonstrate Significant Efficacy And Excellent Safety For BF-200 ALA Treatment Of Superficial Skin Cancer - LEVERKUSEN, Germany, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, presents data from three pivotal Phase III trials for its lead drug candidate BF-200 ALA at the 14th Annual South Beach Symposium.
01/28/16 01:53 PMPTA-Adhoc: Biofrontera AG: Biofrontera's Ameluz® achieves excellent results in clinical study for basal cell carcinoma - Leverkusen, Germany (pta011/28.01.2016/10:15) - Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, has received preliminary phase III study results for the treatment of basal cell carcinoma using PDT, photodynamic therapy. The results ...
01/27/16 01:22 PMFDA completes mid-cylce review of Biofrontera's Ameluz - With this potential hurdle behind us, we do not anticipate any major delays and we look forward to FDA completing its review in the spring." At 9:58am: (LON:B8F) Biofrontera AG share price was 0p at 135p Story provided by StockMarketWire.com
11/12/15 07:06 AMBiofrontera AG Notice of Third Quarter Results 2015 - [at noodls] - Press Release News Release Biofrontera AG Notice of Third Quarter Results 2015 Leverkusen, Germany, 12 November 2015 - Biofrontera AG (AIM: B8F), the biopharmaceutical company focusing on sun-induced skin ...
08/07/15 01:06 AMBiofrontera AG Notice of First Half Year Results 2015 - [at noodls] - Press Release News Release Biofrontera AG Notice of First Half Year Results 2015 Leverkusen, Germany, 04 August 2015 - Biofrontera AG (AIM: B8F), the European biopharmaceutical company, will be announcing ...
08/07/15 01:01 AMBiofrontera AG: Notice of First Half Year Results 2015 -
05/22/15 09:30 AMNotice of First Quarter Results 2015 - [at noodls] - Press Release News Release Biofrontera AG Leverkusen, Germany, 22 May 2015 - Biofrontera AG (AIM: B8F), the European biopharmaceutical company, will be announcing its results for the first three months ...
05/22/15 09:19 AMBiofrontera AG: Notice of First Quarter Results 2015 -
03/30/15 01:00 AMNotice of Annual Results 2014 - [at noodls] - Press Release News Release Biofrontera AG Biofrontera AG (AIM: B8F), the European biopharmaceutical company, will be announcing its annual results for the twelve months period ending 31 December 2014 on ...

Social

About Biofrontera Ag

No company description available

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: B8F
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $141.22
  • 200 Day Moving Average: $163.20
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $N/A EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: